

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**北京市春立正達醫療器械股份有限公司**  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
(*A joint stock limited company incorporated in the People's Republic of China with limited liabilities*)  
(Stock Code: 1858)

## **POLL RESULTS OF THE ADJOURNED H SHAREHOLDERS' CLASS MEETING**

Reference is made to the circular of Beijing Chunlizhengda Medical Instruments Co., Ltd.\* (the “**Company**”) dated 27 May 2024 (the “**Circular**”), the notice of the H Shareholders’ Class Meeting dated 27 May 2024 (the “**Notice**”) and the announcement in relation to the adjournment of H Shareholders’ Class Meeting dated 26 June 2024 (the “**Announcement**”). Unless the context requires otherwise, terms used herein shall have the same respective meanings as those defined in the Circular, the Notice and the Announcement.

### **CONVENING AND ATTENDANCE OF THE ADJOURNED H SHAREHOLDERS' CLASS MEETING**

The Adjourned H Shareholders’ Class Meeting of the Company (the “**Meeting**”) was held at 2:00 p.m. on Friday, 5 July 2024 at No. 10 Xinmi Xi Er Road, Southern District of Tongzhou Economic Development Zone, Tongzhou District, Beijing, the PRC.

The Meeting was convened by the board of directors of the Company (the “**Board**”) and chaired by Ms. Shi Wenling, chairman of the Board. Voting at the Meeting was conducted by a registered poll onsite. WUYIGE Certified Public Accountants LLP, the Company’s auditor, was appointed by the Company as the scrutineer for the voting.

The convening of the Meeting was in compliance with the requirements of the applicable laws and regulations of the PRC, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the articles of association of the Company.

The total number of issued H Shares of the Company as at the date of the Meeting was 95,140,500 Shares, which was the total number of Shares entitling the H Shareholders to attend and vote for or against or abstain from voting the resolutions proposed at the Meeting.

No party has stated its intention in the Circular that it would vote against any resolution or that it would abstain from voting at the Meeting.

To the best knowledge, information and belief of the directors of the Company, there was no restriction on any shareholder casting votes on any of the proposed resolution at the Meeting. There were no Shares entitling the Shareholders to attend the Meeting and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules and no Shareholders were required under the Listing Rules to abstain from voting at the Meeting.

All Directors attended the Meetings. The attendance record of the Directors at the Meetings was as follows:

- the executive Directors of the Company, Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao attended the Meetings in person; and
- the non-executive Director of the Company, Mr. Wang Xin, and the independent non-executive Directors of the Company, Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie attended the Meetings by telephone.

Details about the attendance of the shareholders and their authorized proxies at the Meeting are set out as follows:

Class of Shares	Number of shareholders and authorised proxies attending the Adjourned H Shareholders' Class Meeting	Total number of the H Shares held by the attendees	Percentage of the total number of H Shares of the Company	
The H Shareholders' Class Meeting	H Shares	1	11,559,938	12.15%

## **POLL RESULTS OF THE ADJOURNED H SHAREHOLDERS' CLASS MEETING**

The poll results of the resolution proposed at the Meeting are as follows:

<b>Special resolution</b>	<b>Number of votes &amp; percentage of the total voting shares at the H Shareholders' Class Meeting (%)</b>		
	<b>For</b>	<b>Against</b>	<b>Abstained</b>
1. To consider and approve the grant of the general mandate to the Board of Directors to repurchase the H Shares of the Company	11,559,938 (100%)	0 (0%)	0 (0%)
As more than two-thirds of the votes were cast in favour of this resolution, the resolution was duly passed as a special resolution.			

For the full text of the resolution, please refer to the Circular of the Company dated 27 May 2024.

### **LEGAL ADVISERS AS TO PRC LAWS**

The Meeting was witnessed by lawyers from V&T Law Firm, Beijing, the PRC legal adviser of the Company, who concluded that the convening and convening procedures of the Meeting are in compliance with the relevant requirements of the laws, administrative regulations and the articles of association of the Company. The eligibilities of the attendees, the convener of the Meeting and the procedures and results of voting at the Meeting were legal and valid.

By order of the Board  
**Beijing Chunlizhengda Medical Instruments Co., Ltd.\***  
Shi Wenling  
Chairman

Beijing, the PRC, 5 July 2024

*As at the date of this announcement, the executive directors of the Company are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Ms. Xu Hong, Mr. Wong Tak Shing and Mr. Weng Jie.*

\* For identification purposes only